Big pharma, Partnering, Pharma

Janssen and Vectura partner for anti-inflammatory therapies for asthma/COPD

Posted on 07 January 2015

Tags: , , , ,

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD.

The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

The collaboration will leverage Vectura’s expertise and proprietary dry powder inhaler technologies in the development of inhaled therapeutics.

Vectura will apply its delivery technologies to develop Janssen’s pulmonary products into late-stage clinical development and commercialisation.

Janssen will lead the clinical development programmes, with Vectura taking responsibility for pharmaceutical development and preparation for Phase II clinical trials.

The deal comprises upfront and development milestones and a tiered royalty on net sales. Financial terms of the agreement are not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

 

Print Friendly, PDF & Email

Leave a Reply